Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Filed with BSE · · 9 pages · English
Summary by 6ix AI
The filing states that Mr. Amol Laxmikant Mujumdar, the Promoter and Managing Director, acquired a specific number of equity shares through the open market. This acquisition represents a small percentage of the total issued and paid-up share capital of the company. The document requests the BSE to record this disclosure accordingly.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Goldline Pharmaceutical Ltd. on 6ix
Earlier from Goldline Pharmaceutical
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- Goldline Pharmaceutical Ltd. Press Release Aug 31 2026
- Shareholder Meeting / Postal Ballot-Outcome of AGM
- Goldline Pharmaceutical Ltd. Press Release Aug 29 2026
- Goldline Pharmaceutical Ltd. Press Release Aug 07 2026
Later from Goldline Pharmaceutical
All Goldline Pharmaceutical news releasesFollow Goldline Pharmaceutical into a list and get an email when it puts out news.
Follow Goldline Pharmaceutical